



ISCO3 Recommendation based on the preliminary results about the use of O₂/O₃ in the treatment /prevention of Novel Coronavirus Pneumonia (COVID-19).

Security alert: MAH volume > 100 mL // Risk of thrombus in COVID-19 + Patients

<p>ISCO3 Theoretical protocol for Intervention in case of Mild /Moderate /Severe COVID-19 + CRITICAL O₂/O₃ NON-considering</p>	<p>O₃SS 5 →3 µg/mL (bub.) 250 mL, Daily x 10 d Or MAH Blood vol. 100 mL. <i>Only in patients with normal d dimer values</i> O₂/O₃: Blood 1:1. Daily for 5 days + 3 weekly x 10/14 days. Firs week 30 µg/mL, last 40 µg/mL or EBOO (not yet outcome)</p>	<p>Consider glutathione 1.2 g or / and Vitamin C 1-3 g in 100 mL of saline. Two times a week for 4 weeks Prelim. Dada Indicate ↑ success of O₃SS</p>																								
<p>Intervention alternative when O₃SS or MAH are not available RIO₃: 1 every 12 h for 14 days</p>	<table border="1" data-bbox="667 584 975 689"> <thead> <tr> <th>RIO₃</th> <th>Conc.</th> <th>Vol.</th> <th>Dose (mg)</th> </tr> </thead> <tbody> <tr> <td>Day 1 / 2</td> <td>20</td> <td>100</td> <td>2</td> </tr> <tr> <td>Day 3 / 4</td> <td>25</td> <td>150</td> <td>3.75</td> </tr> <tr> <td>Day 5 / 6</td> <td>30</td> <td>150</td> <td>4.5</td> </tr> <tr> <td>Day 7 / 8</td> <td>35</td> <td>200</td> <td>7</td> </tr> <tr> <td>Day 8-14</td> <td>40</td> <td>200</td> <td>8</td> </tr> </tbody> </table> <p>+ MiAH 5 mL Blood + 5 mL O₃ 90 µg/mL, Once a week for 4 weeks.</p>	RIO ₃	Conc.	Vol.	Dose (mg)	Day 1 / 2	20	100	2	Day 3 / 4	25	150	3.75	Day 5 / 6	30	150	4.5	Day 7 / 8	35	200	7	Day 8-14	40	200	8	<p>Support: <i>Archiv of Medical Research</i> 2005. 36 (5):549–54 // <i>Virulence</i> 1(3), 2010: 215-217. // <i>Ozone: Science & Engineering</i> 2012.34: 451-458 // <i>Ozone: Science & Engineering</i>, 2016 38 (322-345).</p> <p>Oral Therapy: Probiotic plus supplementation proposed in Prevention protocol ↓</p>
RIO ₃	Conc.	Vol.	Dose (mg)																							
Day 1 / 2	20	100	2																							
Day 3 / 4	25	150	3.75																							
Day 5 / 6	30	150	4.5																							
Day 7 / 8	35	200	7																							
Day 8-14	40	200	8																							
<p>ISCO3 Theoretical protocol for Prevention Medical doctor or occupational risk people</p>	<p>MiAH 5 mL Blood + session 1/2: 5 mL O₃ 25 µg/mL; session 3/4: 5 mL O₃ 30 µg/mL; session 5/6: 5 mL O₃ 30 µg/mL. Once a week. Or Rectal insufflation 3 times a week 40 µg/mL /100 mL</p>	<p>Consider: glutathione 600 mg or / and Vit. C 1 g in 100 mL of saline i.v. once a week. Oral: Once a day: N-acetyl cysteine 600 mg for 30 days, plus Vit.D 2000 UI (o 50 µg). Twice a day Vit. C 500 mg. Melatonin 3/5 mg 30 min before sleep.</p>																								
<p>ISCO3 Theoretical protocol for Recovery</p>	<p>Rectal insufflation 2 times a week 30 µg/mL /100 mL, to complete 20 session, then 2 months off. Repeat treatment cycles until complete remission</p>	<p>Oral: Once a day: N-acetyl cysteine 600 mg 30 days off / 30 days on, plus Vit.D 2000 UI (o 50 µg). Twice a day Vit. C 300 mg, Zn 5 mg. Melatonin 3/5 mg 30 min before sleep.</p>																								
<p>Personal Protective Equipment Disinfection</p>	<p>O₃ concentration >15 µg/mL Contact time: >10 min Humidity: 99 %</p>	<p>Ref: <i>Antioxidants</i> 2020, 9, 1222; doi:10.3390/antiox9121222</p>																								

Ozone in Personal Protective Equipment Disinfection

Bernardino Clavo, Elizabeth Córdoba-Lanús, Francisco Rodríguez-Esparragón, Sara E. Cazorla-Rivero, Omar García-Pérez, José E. Piñero, Jesús Villar, Ángeles Blanco, Cristina Torres-Ascensión, José L. Martín-Barrasa, Jesús M. González-Martin, Pedro Serrano-Aguilar and Jacob Lorenzo-Morales. Effects of Ozone Treatment on Personal Protective Equipment Contaminated with SARS-CoV-2. *Antioxidants* 2020, 9, 1222; doi:10.3390/antiox9121222

Ozone in Environments Disinfection

F De Caro, G Moccia, A Borrelli, A Anecchiarico, G Cioffi, A Campanella, O Motta, V Caputo, G Boccia, and M Capunzo. SARS-CoV-2: Sanitize a hospital *Eur J Public Health*. 2020 Sep; 30(Suppl 5): ckaa166.716. doi: [10.1093/eurpub/ckaa166.716](https://doi.org/10.1093/eurpub/ckaa166.716)

Reference:

Bocci V. *et al.* (2010) Ozonation of human HIV-infected plasmas for producing a global vaccine: How HIV-patients may help fight the HIV pandemia. *Virulence* 1(3) 215-217.

Hernández Rosales *et al.* (2005) Ozone therapy effects on biomarkers and lung function in asthma. *Archiv of Medical Research* 36 (5):549–54

Jeffrey I Mechanick *et al.* Clinical Nutrition Research and the COVID-19 Pandemic: A Scoping Review of the ASPEN COVID-19 Nutrition Taskforce *JPEN J Parenter Enteral Nutr*. 2020 Oct 23. doi: 10.1002/jpen.2036. Online ahead of print.

Mawsouf M.N *et al.* Ozone Therapy in Patients with Viral Hepatitis C. Ten Years of Experience (2012). *Ozone: Science & Engineering* 34: 451-458

Viebahn-Hänsler *et al.* (2016). Ozone in Medicine: Clinical Evaluation and Evidence Classification of the Systemic Ozone Applications, Major Autohemotherapy and Rectal Insufflation, According to the Requirements for Evidence-Based Medicin. *Ozone: Science & Engineering*, 38 (322-345).

The up-date of these recommendations take into consideration the preliminary results listed in “ISCO3 follow-up of the original paper with outcomes”.

Please, refer any up-date / side effect by E.mail: info@isco3.org